Investigational medications in 9,638 hospitalized patients with severe COVID-19: lessons from the “fail-and-learn” strategy during the first two waves of the pandemic in 2020

Patient Safety in Surgery

Research

Christina Colosimo¹  Adam C. Delgado¹  Brendon Cornett²  Oliwier Dziadkowiec²  Ye Ji Choi²  Philip F. Stahel³  Vincent P. Stahel⁴ 

[1] Department of Surgery, Sky Ridge Medical Center, 80124, Lone Tree, CO, USA;Graduate Medical Education, HCA Healthcare Continental Division, 80237, Denver, CO, USA;Mission Health, HCA Healthcare North Carolina Division, 28803, Asheville, NC, USA;Department of Surgery, Brody School of Medicine, East Carolina University, 27858, Greenville, NC, USA;Department of Specialty Medicine, College of Osteopathic Medicine, Rocky Vista University, 80134, Parker, CO, USA;University of Colorado, 80309, Boulder, CO, USA;

关键词: COVID-19;    Corticosteroids;    Remdesivir;    Azithromycin;    Hydroxychloroquine;    Tocilizumab;    Mechanical ventilation;    Mortality.;   

DOI  :  10.1186/s13037-023-00358-9

 received in 2023-02-16, accepted in 2023-03-23,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe early surge of the novel coronavirus disease 2019 (COVID-19) pandemic introduced a significant clinical challenge due to the high case-fatality rate in absence of evidence-based recommendations. The empirical treatment modalities were relegated to historical expertise from the traditional management of acute respiratory distress syndrome (ARDS) in conjunction with off-label pharmaceutical agents endorsed under the “emergency use authorization” (EUA) paradigm by regulatory agencies. This study was designed to evaluate the insights from the “fail-and-learn” strategy in 2020 before the availability of COVID-19 vaccines and access to reliable insights from high-quality randomized controlled trials.MethodsA retrospective, multicenter, propensity-matched, case-control study was performed on a data registry comprising 186 hospitals from a national health care system in the United States, designed to investigate the efficacy of empirical treatment modalities during the early surge of the COVID-19 pandemic in 2020. Reflective of the time-windows of the initial two surges of the pandemic in 2020, patients were stratified into “Early 2020” (March 1–June 30) versus “Late 2020” (July 1–December 31) study cohorts. Logistic regression was applied to determine the efficacy of prevalent medications (remdesivir, azithromycin, hydroxychloroquine, corticosteroids, tocilizumab) and supplemental oxygen delivery modalities (invasive vs. non-invasive ventilation) on patient outcomes. The primary outcome measure was in-hospital mortality. Group comparisons were adjusted for covariates related to age, gender, ethnicity, body weight, comorbidities, and treatment modalities pertinent to organ failure replacement.ResultsFrom a total of 87,788 patients in the multicenter data registry screened in this study, 9,638 patients were included who received 19,763 COVID-19 medications during the first two waves of the 2020 pandemic. The results showed a minimal, yet statistically significant, association with hydroxychloroquine in “Early 2020” and remdesivir in “Late 2020” with reduced odds of mortality (odds ratios 0.72 and 0.76, respectively; P = 0.01). Azithromycin was the only medication associated with decreased odds of mortality during both study time-windows (odds ratios 0.79 and 0.68, respectively; P < 0.01). In contrast, the necessity for oxygen supply showed significantly increased odds of mortality beyond the effect of all investigated medications. Of all the covariates associated with increased mortality, invasive mechanical ventilation had the highest odds ratios of 8.34 in the first surge and 9.46 in in the second surge of the pandemic (P < 0.01).ConclusionThis retrospective multicenter observational cohort study on 9,638 hospitalized patients with severe COVID-19 revealed that the necessity for invasive ventilation had the highest odds of mortality, beyond the variable effects observed by administration of the prevalent EUA-approved investigational drugs during the first two surges of the early 2020 pandemic in the United States.

【 授权许可】

CC BY   
© The Author(s) 2023. corrected publication 2023

【 图 表 】

12888_2023_4816_Article_IEq4.gif

Fig. 1

Fig. 2